MedPath
Found 29 clinical trials|View Analysis
Sort by:

Total Neoadjuvant Therapy for Adenocarcinoma of the OESophagus and Oesophagogastric Junction: TNT-OES-2 Trial

Phase 2
Not yet recruiting
Conditions
Adenocarcinoma of the Esophagus
Esophageal Cancer
Interventions
Drug: FLOT-CROSS or CROSS-FLOT
First Posted Date
2023-12-08
Last Posted Date
2023-12-08
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
216
Registration Number
NCT06161818

A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction

Not Applicable
Conditions
Esophageal Cancer
Interventions
Other: BIRC3
First Posted Date
2020-02-13
Last Posted Date
2020-04-17
Lead Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Target Recruit Count
128
Registration Number
NCT04269083

Siewert Type I-II: CT, PET-CT, EUS Sensitivity/Specificity for the Assessment of Lymph Node Metastases

Completed
Conditions
Siewert Type I-II Adenocarcinoma of the Esophagus
Interventions
Procedure: esophagectomy
First Posted Date
2018-05-21
Last Posted Date
2018-05-21
Lead Sponsor
University of Bologna
Target Recruit Count
101
Registration Number
NCT03529968
Locations
🇮🇹

Department of Medical and Surgical Sciences University of Bologna, Bologna, Bo, Italy

Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA

Phase 1
Withdrawn
Conditions
Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Squamous Cell Carcinoma of the Esophagus
Interventions
First Posted Date
2017-10-12
Last Posted Date
2017-12-19
Lead Sponsor
Jules Bordet Institute
Registration Number
NCT03307941
Locations
🇧🇪

Institut Jules Bordet, Brussels, Belgium

Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus

Phase 3
Active, not recruiting
Conditions
Esophageal Adenocarcinoma (UICC TNM7)
Adenocarcinoma of the Esophagogastric Junction
Interventions
First Posted Date
2015-07-28
Last Posted Date
2024-05-08
Lead Sponsor
University Hospital Schleswig-Holstein
Target Recruit Count
438
Registration Number
NCT02509286
Locations
🇩🇪

Ruppiner Kliniken GmbH, Neuruppin, Germany

🇩🇪

Klinikum Dortmund gGmbH, Dortmund, Germany

🇩🇪

Uniklinik Köln, Köln, Germany

and more 27 locations

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Phase 1
Withdrawn
Conditions
Stage IIIA Esophageal Cancer
Stage IIIA Gastric Cancer
Stage IIIB Esophageal Cancer
Stage IIIB Gastric Cancer
Adenocarcinoma of the Esophagus
Intestinal Adenocarcinoma of the Stomach
Adenocarcinoma of the Gastroesophageal Junction
Mixed Adenocarcinoma of the Stomach
Stage IIIC Esophageal Cancer
Stage IIIC Gastric Cancer
Interventions
Drug: c-Met inhibitor AMG 337
Other: placebo
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Other: pharmacological study
Other: laboratory biomarker analysis
First Posted Date
2015-01-26
Last Posted Date
2023-05-25
Lead Sponsor
Eastern Cooperative Oncology Group
Registration Number
NCT02344810
Locations
🇺🇸

ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.

Phase 2
Completed
Conditions
Adenocarcinoma of the Esophagus or Esophagogastric Junction
Interventions
Radiation: Radiation therapy
Drug: Oxaliplatin and fluorouracil.
First Posted Date
2014-09-16
Last Posted Date
2020-02-28
Lead Sponsor
Lund University Hospital
Target Recruit Count
29
Registration Number
NCT02241499
Locations
🇸🇪

Lund University Hospital, Department of Oncology, Lund, Sweden

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

Phase 2
Active, not recruiting
Conditions
Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Stage IIIC Esophageal Cancer
Adenocarcinoma of the Gastric Cardia
Stage IIIA Esophageal Cancer
Stage IIIB Esophageal Cancer
Interventions
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Procedure: therapeutic conventional surgery
Radiation: radiation therapy
Drug: carboplatin
Drug: paclitaxel
First Posted Date
2014-01-15
Last Posted Date
2024-01-08
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
63
Registration Number
NCT02037048
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Nodal Status in Adenocarcinoma of the Esophagus an Cardia

Completed
Conditions
Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastric Cardia
Interventions
Procedure: Subtotal esophagectomy and gastric pull up
Procedure: Subtotal esophagectomy at the azygos vein, total gastrectomy
First Posted Date
2012-07-09
Last Posted Date
2012-07-25
Lead Sponsor
University of Bologna
Target Recruit Count
194
Registration Number
NCT01635595
Locations
🇮🇹

Division of Thoracic Surgery, Center for the Study and Therapy of Diseases of the Esophagus. Alma Mater Studiorum - University of Bologna, GVM Care & Research, Maria Cecilia Hospital, Cotignola, Ravenna, Italy

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

Phase 2
Completed
Conditions
Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Diffuse Adenocarcinoma of the Stomach
Intestinal Adenocarcinoma of the Stomach
Mixed Adenocarcinoma of the Stomach
Recurrent Esophageal Cancer
Recurrent Gastric Cancer
Squamous Cell Carcinoma of the Esophagus
Stage IIIB Esophageal Cancer
Stage IIIB Gastric Cancer
Interventions
Drug: cyclodextrin-based polymer-camptothecin CRLX101
Other: Laboratory biomarker analysis
Other: Pharmacological studies
First Posted Date
2012-06-06
Last Posted Date
2018-02-01
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
10
Registration Number
NCT01612546
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

© Copyright 2025. All Rights Reserved by MedPath